2.2. Study Population
COPD, decompensation, active malignant neoplastic disease
COPD, ACD
The study population consists of patients with ACD, their informal caregiver(s), and their healthcare professionals, meeting the following eligibility criteria. Eligible patients will have to meet the below inclusion criteria:Aged over 55;HF in functional stage III/IV according to the NYHA scale and/or stages C and D of the ACCF/AHA classification. Stable phase (at least two months without decompensation requiring hospital care);And/or COPD GOLD scale > 2 (FEV1 < 50) and/or mMRC ≥ 2 and/or CAT ≥ 10 and/or use of oxygen at home;With or without comorbidities;They are able to provide informed consent;They still live and generally plan on living in their home for the intervention duration;They or their informal caregiver(s) are able to use digital technology, communication tools, and/or networks and have access to a computer, laptop, tablet or smartphone and wifi/internet connection;They or their informal caregiver(s) understand, read, and talk the native language.The informal caregiver will be a person who provides occasional or regular support to the patient needs. Caregivers will be eligible if the patient they care for meets the inclusion criteria and is included in the study. Healthcare professionals will be eligible if they are involved in the included patients’ care, are open to new ways of working, specifically as part of a coordinated and collaborative team, and are also open to the use of new technology. Criteria for patient exclusion include an existing diagnosis of an active malignant neoplastic disease, being in any active list of transplantation, or refusing/unable to sign the informed consent. Patients who have withdrawn their participation from ADLIFE will be excluded; caregivers will not be eligible if the patients they care for meet the exclusion criteria; Healthcare professionals not caring for eligible patients will not be included.